	US 11,701,407 B2
	Cytokine conjugates for the treatment of proliferative and infectious diseases
Jerod Ptacin, La Jolla, CA (US); Carolina E. Caffaro, La Jolla, CA (US); and Marcos Milla, La Jolla, CA (US)
Assigned to SYNTHORX, INC., La Jolla, CA (US)
Filed by SYNTHORX, INC., La Jolla, CA (US)
Filed on Feb. 27, 2020, as Appl. No. 16/803,816.
Application 16/803,816 is a division of application No. 16/434,999, filed on Jun. 7, 2019, granted, now 10,610,571.
Application 16/434,999 is a continuation of application No. PCT/US2018/045257, filed on Aug. 3, 2018.
Claims priority of provisional application 62/540,781, filed on Aug. 3, 2017.
Prior Publication US 2020/0188484 A1, Jun. 18, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 47/61 (2017.01); C07K 14/55 (2006.01); C07K 14/715 (2006.01); A61K 38/00 (2006.01); A61K 47/64 (2017.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01)

CPC A61K 38/2013 (2013.01) [A61K 47/542 (2017.08); A61K 47/60 (2017.08); A61K 47/61 (2017.08); A61K 47/643 (2017.08); A61K 47/644 (2017.08); A61K 47/65 (2017.08); A61K 47/68 (2017.08); C07K 14/55 (2013.01); C07K 14/7155 (2013.01); A61K 38/00 (2013.01)]

28 Claims

1. A method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a modified interleukin 2 (IL-2) polypeptide, wherein the modified IL-2 polypeptide comprises:

at least one unnatural amino acid and a conjugating moiety covalently attached via a linker to the at least one unnatural amino acid,

wherein the conjugating moiety is a water-soluble polymer,

wherein the position of the at least one unnatural amino acid is selected from K35, T37, R38, T41, F42, K43, F44, Y45, E60, E61, E62, K64, P65, E68, V69, N71, L72, M104, C105, and Y107 in reference to the amino acid positions within SEQ ID NO: 1, and

wherein the modified IL-2 polypeptide comprises at least 80% sequence identity to SEQ ID NO: 1.